Quotient Sciences
United Kingdom
About Quotient Sciences
16 articles about Quotient Sciences
-
Nanomerics Announces Quotient Sciences as its Clinical Trials Partner
3/28/2022
Nanomerics Ltd., a private speciality pharmaceutical company, announced that the Company had signed an agreement with Quotient Sciences, a drug development and manufacturing accelerator, for the delivery of its Sunlight Trial.
-
Quotient Sciences Acquires Arcinova, the UK-Based Contract Development and Manufacturing Organization
2/9/2021
Quotient Sciences , the drug development and manufacturing accelerator, announced that it has acquired Arcinova , the U.K.-based multiservice contract development and manufacturing organization (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide.
-
Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm
4/28/2020
A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced today by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, and CytoAgents, Inc., a privately held biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 28, 2020.
-
Tufts CSDD Demonstrates Multi-Million-Dollar Benefits of Translational Pharmaceutics®
10/30/2019
The Tufts CSDD study assessed development cycle times and their financial benefits by using data compiled on completed Translational Pharmaceutics projects to benchmark against industry drug development durations.
-
Quotient Sciences Appoints Claes Glassell as Non-Executive Chairman of Board of Directors
10/22/2019
Glassell has held numerous leadership positions, including at the board level, to help companies through high phases of growth.
-
Quotient Sciences to Recapitalize With Global Private Equity Firm Permira
7/18/2019
Quotient Sciences and global investment firm Permira announced that a company backed by the Permira Funds has signed a definitive agreement to acquire a majority stake in Quotient from companies controlled by GHO Capital and other investors for an undisclosed sum.
-
Quotient Sciences Constructs State-of-the-Art Early-Phase Formulation and Manufacturing Facility in U.S.
10/16/2018
Quotient Sciences announces a significant expansion to its operations in the U.S. with the opening of a state-of-the-art, 45,000-square-foot facility located near Philadelphia, in Garnet Valley, Pa.
-
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug Development
1/16/2018
The companies will jointly support pediatric drug development for clients from concept to market launch through a unique end-to-end service that will speed delivery of pediatric medicines.
-
Quotient Sciences Launches as the New Global Identity for Quotient Clinical
11/10/2017
Quotient Clinical announces its renaming to Quotient Sciences (Quotient), following the acquisitions of Co-Formulate, QS Pharma and SeaView Research.
-
Quotient Clinical Signs Agreement With Nuformix to Evaluate Cocrystal Formulations Using Translational Pharmaceutics
10/19/2017
Under the deal, Quotient will use its Translational Pharmaceutics platform to develop a formulated oral NXP001 cocrystal product and validate its performance in healthy subjects.
-
QS Pharma Receives Approval From EMA For Commercial Manufacture
6/27/2017
-
Quotient Clinical Appoints Azhar Kalim As Chief Commercial Officer
5/30/2017
-
Quotient Clinical Announces Second U.S. Acquisition: QS Pharma
2/14/2017
-
Quotient Clinical Expands Into U.S.A. Through Acquisition Of Seaview Research, The Specialist Clinical Pharmacology Business
2/6/2017
-
Quotient Clinical Expands Data Sciences Capability
9/27/2016